SCHEMBL9962256

SCHEMBL9962256

C=CCOC(=O)[C@@H](NC(=O)[C@H](Cc1cccc2ccccc12)NC(=O)OC(C)(C)C)C(C)C

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSK P43235 6/20 0.59
CTSS P25774 5/20 0.59
CASP3 P42574 1/20 0.47
CTSD P07339 2/20 0.44
MMP9 P14780 1/20 0.43
MMP8 P22894 1/20 0.43
MMP14 P50281 1/20 0.43
CTSB P07858 1/20 0.43
TP53 P04637 1/20 0.42
MAPT P10636 1/20 0.42
CTSL P07711 2/20 0.42
CYP3A4 P08684 1/20 0.41
PSEN1 P49768 3/20 0.41
PSEN2 P49810 3/20 0.41
APH1B Q8WW43 3/20 0.41
NCSTN Q92542 3/20 0.41
APH1A Q96BI3 3/20 0.41
PSENEN Q9NZ42 3/20 0.41
CASP1 P29466 1/20 0.41
TACR1 P25103 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9962153 0.87 CASP3 (0.59) CTSKCTSSCASP3CTSDCTSB
SCHEMBL5557360 0.85 CTSS (0.66) CTSKCTSSCASP3CTSDMMP9
SCHEMBL16770356 0.83 CASP3 (0.46) CTSKCTSSCASP3CTSDMMP9
SCHEMBL7878105 0.82 CTSD (0.44) CTSKCTSSCASP3CTSDMMP9
SCHEMBL17137921 0.80 CTSS (0.77) CTSKCTSSMMP9MMP8MMP14
SCHEMBL17137918 0.80 CTSS (0.77) CTSKCTSSMMP9MMP8MMP14
SCHEMBL23771802 0.80 CTSS (0.56) CTSKCTSSCASP3CTSDCTSB
SCHEMBL9962288 0.80 CASP3 (0.60) CTSKCASP3CTSDCTSBCTSL
SCHEMBL16459632 0.79 CTSS (0.66) CTSKCTSSMMP9MMP8MMP14
SCHEMBL16459631 0.79 CTSS (0.66) CTSKCTSSMMP9MMP8MMP14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9045524-B2 Selective caspase inhibitors and uses thereof NOVAGENESIS FOUNDATION (CH) 2015-06-02 US disclosed
US-20120157394-A1 SELECTIVE CASPASE INHIBITORS AND USES THEREOF NEW WORLD LABORATORIES, INC. (CA) 2012-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157394-A1 SELECTIVE CASPASE INHIBITORS AND USES THEREOF CASP1, VIP, CASP5 CTSK 90/4885CTSS 73/4885CASP3 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.